Catalyst Event
Akeso Inc (9926) · Other
From Akros SCHK HK-U.S. Biotech Index (ASHUBIO)
6/1/2026, 12:00:00 AM
Akeso announced that its drug Ivonescimab plus chemotherapy showed a 34% reduction in the risk of death in the Phase III HARMONi-6 trial for first-line advanced squamous non-small cell lung cancer. The landmark results were presented at the ASCO 2026 Plenary Session and published in The Lancet. High importance is estimated due to the significant clinical success in a major indication, likely resulting in >10% price impact scheduled.
Korean Translation
康方生物, 자사 약물 이보시맙(Ivonescimab)과 화학요법 병용이 1차 진행성 편평 비소세포폐암(sq-NSCLC) 대상 HARMONi-6 3상 임상시험에서 사망 위험을 34% 감소시켰다고 발표함. 이 획기적인 결과는 ASCO 2026 본회의에서 발표되었고 '더 랜싯(The Lancet)'에 게재됨. 주요 적응증에서의 유의미한 임상 성공으로 10% 이상의 주가 영향이 예상됨.
Related Recent Events
Pfizer Inc (PFE) · Earnings Release
Pfizer Q2 2026 earnings release on 2026-08-04; Low importance estimated as it is a routine event, scheduled
8/4/2026, 12:00:00 AM
Bristol-Myers Squibb Co (BMY) · Earnings Release
Q2 2026 earnings results are scheduled to be released on 2026-07-30. A market reaction of >1% is estimated upon the actual release scheduled.
7/30/2026, 12:00:00 AM
Abbott Laboratories (ABT) · Earnings Release
Abbott is expected to announce its Q2 2026 earnings results on July 16, 2026. This key quarterly financial update is estimated to have a moderate price impact of at least 5%, scheduled.
7/16/2026, 12:00:00 AM
Hansoh Pharmaceutical Group Company Limited (3692) · Other
Annual General Meeting on June 26, 2026, to approve 2025 results and dividends. Analysts estimate a 1-5% price impact for this routine corporate event scheduled.
6/26/2026, 12:00:00 AM
United Laboratories International Holdings Ltd (3933) · Other
The Annual General Meeting is scheduled for June 23, 2026, to vote on financial statements and a potential 20% share issuance mandate which could dilute existing shareholdings; high importance due to potential dilution, scheduled.
6/23/2026, 12:00:00 AM
Merck and Co Inc (MRK) · Other
FDA action date (PDUFA) for supplemental applications for WELIREG in combination with KEYTRUDA for the adjuvant treatment of certain patients with renal cell carcinoma (RCC) is scheduled for June 19, 2026, scheduled.
6/19/2026, 12:00:00 AM